Targets › TNFSF12
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2028.
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. (UniProt, O43508)
Open in Phaseline: the race on TNFSF12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangsu HengRui Medicine | Adabelimumab TWEAK/TNF superfamily ligand antagonist | TNFSF12 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Oct 2028 |
Locally Advanced or Metastatic Non-small Cell Lung Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.